Agilent Technologies, Inc. $A Shares Sold by SVB Wealth LLC

Key Points

• SVB Wealth LLC reduced its stake in Agilent Technologies by 42.9%, selling 23,981 shares and ending up with 31,905 shares valued at approximately $3.73 million.
• In related investor activity, several firms, including Whipplewood Advisors LLC and Sunbelt Securities Inc., significantly increased their holdings in Agilent Technologies, with Whipplewood increasing by 286.2% in the first quarter.
• Agilent Technologies reported a strong quarterly performance with an earnings per share (EPS) of $1.31, beating estimates, and an expected FY 2025 EPS range guidance of 5.540-5.610.

SVB Wealth LLC trimmed its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 42.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,905 shares of the medical research company's stock after selling 23,981 shares during the period. SVB Wealth LLC's holdings in Agilent Technologies were worth $3,732,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in A. Vanguard Group Inc. grew its stake in shares of Agilent Technologies by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company's stock worth $3,908,141,000 after acquiring an additional 240,965 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Agilent Technologies by 2.5% in the first quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company's stock worth $624,888,000 after buying an additional 128,131 shares during the period. Deutsche Bank AG raised its stake in shares of Agilent Technologies by 0.9% in the fourth quarter. Deutsche Bank AG now owns 4,436,700 shares of the medical research company's stock worth $596,026,000 after buying an additional 38,348 shares during the period. Northern Trust Corp grew its position in shares of Agilent Technologies by 12.3% during the fourth quarter. Northern Trust Corp now owns 4,192,790 shares of the medical research company's stock worth $563,259,000 after purchasing an additional 457,713 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Agilent Technologies by 9.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,231,981 shares of the medical research company's stock worth $434,184,000 after purchasing an additional 283,445 shares in the last quarter.

Agilent Technologies Trading Up 0.4%

Shares of NYSE A traded up $0.53 during trading on Wednesday, hitting $118.83. 1,681,460 shares of the company traded hands, compared to its average volume of 1,941,331. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $153.84. The company has a 50-day moving average price of $117.93 and a 200-day moving average price of $116.88. The firm has a market capitalization of $33.76 billion, a P/E ratio of 29.34, a P/E/G ratio of 3.62 and a beta of 1.22. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting analysts' consensus estimates of $1.37. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on A shares. Wall Street Zen upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Leerink Partners lifted their target price on Agilent Technologies to $135.00 and gave the company a "buy" rating in a research report on Friday, May 30th. JPMorgan Chase & Co. reduced their price target on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research report on Thursday, May 29th. TD Cowen boosted their price target on Agilent Technologies to $150.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Finally, Barclays boosted their price objective on Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a report on Tuesday, June 24th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $138.83.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. The trade was a 3.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.